Back to Search
Start Over
Novel Functional Imaging of Neuroendocrine Tumors
- Source :
- Endocrinology and Metabolism Clinics of North America. 47:505-523
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- Somatostatin receptor imaging constitutes an integral part in neuroendocrine tumor visualization and should, because of its vastly superior performance, use 68Ga-DOTA-somatostatin analogue-PET/computed tomography rather than scintigraphy; it is particularly valuable for detecting metastases to lymph nodes, bone, peritoneum, and liver, which may be missed by morphologic imaging. 18FDG-PET/computed tomography is better suited for G3 and high-G2 neuroendocrine tumors. 18FDG-PET/computed tomography provides prognostic information. Alternative available PET tracers are 18F-DOPA and 11C-5-hydroxytryptophan. To take full advantage of the technique PET/computed tomography should include diagnostic intravenous contrast-enhanced computed tomography. PET/MRI is currently mainly investigational.
- Subjects :
- medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
Computed tomography
Neuroendocrine tumors
Scintigraphy
Multimodal Imaging
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Endocrinology
Peritoneum
Humans
Medicine
Pet tracer
medicine.diagnostic_test
business.industry
Somatostatin receptor
medicine.disease
Magnetic Resonance Imaging
Functional imaging
Neuroendocrine Tumors
18f dopa
medicine.anatomical_structure
Positron-Emission Tomography
030220 oncology & carcinogenesis
Radiology
Radiopharmaceuticals
Tomography, X-Ray Computed
business
Subjects
Details
- ISSN :
- 08898529
- Volume :
- 47
- Database :
- OpenAIRE
- Journal :
- Endocrinology and Metabolism Clinics of North America
- Accession number :
- edsair.doi.dedup.....1746847607e3a59c5c45b0995de8f5d2
- Full Text :
- https://doi.org/10.1016/j.ecl.2018.04.003